RS47 is a potent and specific inhibitor of the non-canonical NF-κB signaling pathway through disrupting RelB binding to its target DNA with a Kd values of 1.1 μM. It is shown to inhibit colorectal cancer (CRC) cells and B lymphoma growth, holds potential as a research tool for targeting cancers driven by hyperactive non-canonical NF-κB […]

RS47 is a potent and specific inhibitor of the non-canonical NF-κB signaling pathway through disrupting RelB binding to its target DNA with a Kd values of 1.1 μM. It is shown to inhibit colorectal cancer (CRC) cells and B lymphoma growth, holds potential as a research tool for targeting cancers driven by hyperactive non-canonical NF-κB […]

RS47 is a potent and specific inhibitor of the non-canonical NF-κB signaling pathway through disrupting RelB binding to its target DNA with a Kd values of 1.1 μM. It is shown to inhibit colorectal cancer (CRC) cells and B lymphoma growth, holds potential as a research tool for targeting cancers driven by hyperactive non-canonical NF-κB […]

LXG6403 is a bi-thiazole potent inhibitor of LOX cellular activity with an IC50 of 1.3 μM. It exhibits anti-cancer activity by remodeling the extracellular matrix, enhancing chemotherapy penetration, inducing ROS generation, and promoting DNA damage-mediated cell death to overcome chemotherapy resistance in triple-negative breast cancer.

LXG6403 is a bi-thiazole potent inhibitor of LOX cellular activity with an IC50 of 1.3 μM. It exhibits anti-cancer activity by remodeling the extracellular matrix, enhancing chemotherapy penetration, inducing ROS generation, and promoting DNA damage-mediated cell death to overcome chemotherapy resistance in triple-negative breast cancer.

LXG6403 is a bi-thiazole potent inhibitor of LOX cellular activity with an IC50 of 1.3 μM. It exhibits anti-cancer activity by remodeling the extracellular matrix, enhancing chemotherapy penetration, inducing ROS generation, and promoting DNA damage-mediated cell death to overcome chemotherapy resistance in triple-negative breast cancer.

Asandeutertinib (Osimertinib-d3, AZD-9291-d3) is an orally administered, ATP-competitive, irreversible, deuterated third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) and a deuterium-stabilized derivative of osimertinib, with the potential to treat advanced EGFR-mutated NSCLC.

Asandeutertinib (Osimertinib-d3, AZD-9291-d3) is an orally administered, ATP-competitive, irreversible, deuterated third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) and a deuterium-stabilized derivative of osimertinib, with the potential to treat advanced EGFR-mutated NSCLC.

LXG6403 is a bi-thiazole potent inhibitor of LOX cellular activity with an IC50 of 1.3 μM. It exhibits anti-cancer activity by remodeling the extracellular matrix, enhancing chemotherapy penetration, inducing ROS generation, and promoting DNA damage-mediated cell death to overcome chemotherapy resistance in triple-negative breast cancer.

Asandeutertinib (Osimertinib-d3, AZD-9291-d3) is an orally administered, ATP-competitive, irreversible, deuterated third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) and a deuterium-stabilized derivative of osimertinib, with the potential to treat advanced EGFR-mutated NSCLC.